Intuitive Surgical Reports Strong Q2 Growth While Guiding to Slowest Expansion in Years

Intuitive Surgical reported second-quarter revenue of $2.89 billion and adjusted earnings of $2.80 per share, beating analyst forecasts but triggering a stock decline due to guidance indicating the company's slowest growth phase in years. The robotic surgery innovator expanded its procedure volumes and installed equipment base, though market concerns about decelerating expansion momentum dominated investor sentiment following the announcement.

Earnings Beat and Operational Expansion

The company delivered adjusted net income of $1.00 billion against second-quarter revenue that climbed 19% from $2.44 billion in the prior-year period. Earnings per share of $2.80 exceeded the analyst consensus estimate of $2.51, while revenue expectations of $2.83 billion were slightly undershot. On a GAAP basis, net income reached $818 million, or $2.29 per share, compared with $658 million, or $1.81 per share, in the same quarter the previous year.

Worldwide procedures combining the da Vinci and Ion platforms expanded approximately 16% year-over-year. The company deployed 468 da Vinci surgical systems during the quarter, up from 395 units a year earlier, including 246 of the newer da Vinci 5 model against 180 previously. Ion endoluminal system placements totaled 55 units compared with 54 in the equivalent period last year.

Installed Base Growth and Market Positioning

The da Vinci installed base reached 11,710 systems globally as of June 30, representing a 12% increase from 10,488 systems the prior year. The Ion endoluminal platform showed stronger expansion momentum, with its installed base growing to 1,096 systems—a 21% increase from 905 systems annually. These metrics underscore the company's continued market penetration across both its flagship robotic surgery platform and its newer respiratory diagnostic technology.

Intuitive repurchased 0.9 million shares for $380 million during the quarter and benefited from $28 million in tariff refunds related to prior-period duties paid under international trade regulations. This benefit contributed $0.08 per diluted share to reported earnings.

Forward Outlook and Market Reaction

Despite operational success, the company's forward guidance signaled deceleration in growth rates, prompting the stock decline after the announcement. Analyst expectations centered on faster expansion trajectories, making the guidance adjustment a source of concern even as the company demonstrated double-digit procedure growth and sustained placements of both established and newer product lines.